BUSINESS

Gilead Earnings Beat Street Estimates, Writedown Taken On Cancer Drug

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in
Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral Veklury, but the company reported a net loss as it wrote down the value of its 2020 acquisition of Immunomedics following recent trial results for cancer drug Trodelvy.
More news
IBTimes Logo

Twitter User Growth Rises Amid Musk Takeover

Twitter Inc reported stronger than expected user growth in what could be its last quarter as a public company after agreeing to a $44-billion buyout by billionaire Elon Musk.
A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021.

WHO-backed Vaccine Resolution Wins 24% Support At Moderna

A shareholder proposal calling on Moderna Inc to study transferring production of COVID-19 vaccines to less-developed countries won 24% support from investors on Thursday after it received a rare endorsement from the World Health Organization.
The logo of the Carlyle Group is displayed at the company's office in Tokyo, Japan October 17, 2018.

Carlyle's 41% Profit Rise In First Quarter Misses Estimates

Carlyle Group Inc posted a lower-than-expected 41% year-on-year rise in first-quarter distributable earnings on Thursday, as market volatility prevented the private equity firm from cashing out on assets as much as some analysts expected.

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.